Domainex is a drug discovery company with a reputation for speed and innovation built on an exceptional track record of drug candidate delivery. It has a world class discovery team with an unrivalled track record and three client drug candidates already in clinic.
Domainex reduces industry average drug discovery timelines by as much as 30% through the application of novel proprietary technologies and a highly focussed and integrated approach to medicinal chemistry and computational chemistry. These technologies and Domainex’s approach also enable it to successfully tackle a greater range of drug target classes, such as kinases, proteases, ion channels, proteins involved in epigenetics and protein-protein interactions.
Domainex has applied its unique technologies and focussed discovery approach to enable it to develop its own pipeline of oncology drugs, including inhibitors of the kinases IKKε/TBK1 and a number of epigenetics related lysine methyltransferases.
Domainex's technology and service offerings include:
•Combinatorial Domain Hunting (CDH); a proprietary technology for the expression of protein drug targets and the selection of ligand binding protein constructs
•Development of biochemical binding or activity assays for use in compound screening
•LeadBuilder: virtual hit screening technology
•Lead optimisation (integrated medicinal and computational chemistry)
•Advice and leadership during your drug discovery projects
•DMPK testing support
This profile was automatically created. Find out more about Domainex on their company website or check out their opportunities in the opportunities section of this page.